• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估免疫组织化学和基因表达对乳腺癌雌激素受体蛋白表达定量质量的研究。

Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer.

作者信息

Leen Sas, Steven Van Laere, Marie Dierick Anne, Valérie Duwel, Annemie De Pauw, Gert Van Den Eynden, Peter Van Dam, Luc Dirix, Peter Vermeulen, Filip Lardon

机构信息

Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Oosterveldlaan 24, 2610 Antwerp, Belgium ; Department of Medical Oncology, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium.

Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Oosterveldlaan 24, 2610 Antwerp, Belgium ; Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.

出版信息

Patholog Res Int. 2014;2014:372653. doi: 10.1155/2014/372653. Epub 2014 Mar 6.

DOI:10.1155/2014/372653
PMID:24734208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3964839/
Abstract

Although immunohistochemistry (IHC) is a widely used technique to classify tumors in ER-positive versus ER-negative ones, interlab variabilities can occur. This study aims to investigate the influences of preanalytical and analytical factors on IHC results. For this purpose, the different steps of the preparation of IHC sections and scoring procedures were compared between two participating laboratories and a central lab. There was a significant positive correlation between the IHC results of the participating laboratories and those of the central lab (correlation coefficient > 0.600; P<0.05). Nevertheless, some discordant cases for immunostaining (5.3% for ER and 5.6% for PR) and for scoring (10.5% for PR) occur at site 1. Comparing IHC results with ESR1 gene expression results revealed a significant positive correlation (correlation coefficients > 0.769; P<0.05). PCR results of ER target genes showed some heterogeneity in the ER-signalling pathway. These results suggest that differences in the IHC procedure between these laboratories did not have a big influence on the end result. Nevertheless, discordant cases caused by preanalytical and analytical lab-specific procedures have been identified.

摘要

尽管免疫组织化学(IHC)是一种广泛用于将肿瘤分为雌激素受体(ER)阳性和ER阴性的技术,但实验室间仍可能存在差异。本研究旨在调查分析前和分析因素对免疫组织化学结果的影响。为此,比较了两个参与实验室和一个中心实验室在免疫组织化学切片制备和评分程序的不同步骤。参与实验室的免疫组织化学结果与中心实验室的结果之间存在显著正相关(相关系数>0.600;P<0.05)。然而,在1号位点出现了一些免疫染色不一致的病例(ER为5.3%,PR为5.6%)和评分不一致的病例(PR为10.5%)。将免疫组织化学结果与ESR1基因表达结果进行比较,发现存在显著正相关(相关系数>0.769;P<0.05)。ER靶基因的PCR结果显示ER信号通路存在一些异质性。这些结果表明,这些实验室之间免疫组织化学程序的差异对最终结果影响不大。然而,已经确定了由分析前和分析实验室特定程序引起的不一致病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/a14739bf5e2d/PRI2014-372653.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/44e3d1bb3d01/PRI2014-372653.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/c65a64332592/PRI2014-372653.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/f74750cad610/PRI2014-372653.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/af9d3e2f28a6/PRI2014-372653.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/883dcf146180/PRI2014-372653.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/a14739bf5e2d/PRI2014-372653.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/44e3d1bb3d01/PRI2014-372653.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/c65a64332592/PRI2014-372653.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/f74750cad610/PRI2014-372653.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/af9d3e2f28a6/PRI2014-372653.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/883dcf146180/PRI2014-372653.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4652/3964839/a14739bf5e2d/PRI2014-372653.006.jpg

相似文献

1
Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer.评估免疫组织化学和基因表达对乳腺癌雌激素受体蛋白表达定量质量的研究。
Patholog Res Int. 2014;2014:372653. doi: 10.1155/2014/372653. Epub 2014 Mar 6.
2
Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.常规免疫组织化学/原位杂交与 Oncotype DX qRT-PCR 检测乳腺癌生物标志物状态的一致性,并对其不相符的情况进行了调查,该研究共纳入了 591 例病例。
Hum Pathol. 2020 Oct;104:54-65. doi: 10.1016/j.humpath.2020.07.022. Epub 2020 Aug 3.
3
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.东部肿瘤协作组(ECOG)2197研究中的雌激素和孕激素受体状态:本地实验室与中心实验室免疫组织化学检测结果比较以及中心实验室定量逆转录聚合酶链反应检测结果比较
J Clin Oncol. 2008 May 20;26(15):2473-81. doi: 10.1200/JCO.2007.13.6424.
4
Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.免疫组织化学与聚合酶链反应在评估乳腺癌雌激素受体(ER)、孕激素受体(PR)和Ki-67以及预测病理完全缓解方面的比较
BMC Cancer. 2017 Feb 13;17(1):124. doi: 10.1186/s12885-017-3111-1.
5
Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.免疫组织化学与 RT-qPCR 检测评估乳腺癌患者 ER、PR、HER2 和 Ki67 及亚型的比较。
Breast Cancer Res Treat. 2022 Aug;194(3):517-529. doi: 10.1007/s10549-022-06649-6. Epub 2022 Jul 5.
6
Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.确定石蜡包埋乳腺癌中类固醇激素受体阳性肿瘤细胞分数大小的阈值测定
Cytometry B Clin Cytom. 2005 Mar;64(1):43-52. doi: 10.1002/cyto.b.20045.
7
Estrogen Receptor-α Quantification in Breast Cancer: Concordance Between Immunohistochemical Assays and mRNA-In Situ Hybridization for ESR1 Gene.乳腺癌中雌激素受体-α的定量检测:免疫组织化学检测与 ESR1 基因 mRNA 原位杂交的一致性。
Appl Immunohistochem Mol Morphol. 2020 May/Jun;28(5):347-353. doi: 10.1097/PAI.0000000000000760.
8
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.基于 RT-qPCR 的 PAM50 乳腺癌分型与标准临床分子标志物的一致性。
BMC Med Genomics. 2012 Oct 4;5:44. doi: 10.1186/1755-8794-5-44.
9
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.绝经后激素受体阳性早期乳腺癌患者 ESR1、PGR、ERBB2 和 MKi67 mRNA 表达:ABCGS 试验 6 的结果。
ESMO Open. 2021 Aug;6(4):100228. doi: 10.1016/j.esmoop.2021.100228. Epub 2021 Aug 7.
10
Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.雌激素和孕激素受体的免疫组织化学检测:26个国家150多个实验室内部肿瘤检测结果与外部质量评估材料检测结果的相关性
J Clin Pathol. 2000 Apr;53(4):292-301. doi: 10.1136/jcp.53.4.292.

引用本文的文献

1
Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.识别早期HR+ HER2-复发风险高的乳腺癌患者。
Geburtshilfe Frauenheilkd. 2024 Feb 8;84(2):164-184. doi: 10.1055/a-2238-3199. eCollection 2024 Feb.
2
From fix to fit into the autoptic human brains.从固定到适配于尸检的人类大脑。
Eur J Histochem. 2018 Aug 27;62(3):2944. doi: 10.4081/ejh.2018.2944.
3
Association between the ornithine decarboxylase G316A polymorphism and breast cancer survival.鸟氨酸脱羧酶G316A基因多态性与乳腺癌生存之间的关联。

本文引用的文献

1
Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification.观察者间在实施 2010 年 ASCO/CAP 关于乳腺癌 ER 报告的推荐意见方面的一致性:通过手动量化来一致报告低水平 ER 表达的困难的例证。
Am J Clin Pathol. 2013 Oct;140(4):487-94. doi: 10.1309/AJCP1RF9FUIZRDPI.
2
A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative.关于为何乳腺癌中甾体激素受体的评估应该是定量的,一篇批判性综述。
Ann Oncol. 2013 Jan;24(1):47-53. doi: 10.1093/annonc/mds238. Epub 2012 Jul 30.
3
Oncol Lett. 2015 Jul;10(1):485-491. doi: 10.3892/ol.2015.3201. Epub 2015 May 12.
The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.
96 小时福尔马林固定对浸润性乳腺癌中雌激素受体、孕激素受体和 HER2 表达的免疫组化评估的影响。
Am J Clin Pathol. 2012 May;137(5):691-8. doi: 10.1309/AJCPQRAG67GJRPMT.
4
Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.半定量免疫组织化学检测与 Oncotype DX(®) qRT-PCR 检测雌激素受体和孕激素受体:一项独立的质量保证研究。
Mod Pathol. 2012 Jun;25(6):869-76. doi: 10.1038/modpathol.2011.219. Epub 2012 Feb 3.
5
The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.长时间固定对浸润性乳腺癌中雌激素受体、孕激素受体和 HER2 表达的免疫组织化学评估的影响:一项前瞻性研究。
Am J Surg Pathol. 2011 Apr;35(4):545-52. doi: 10.1097/PAS.0b013e31820e6237.
6
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.雌激素和孕激素受体的半定量免疫组织化学检测与Oncotype DX逆转录聚合酶链反应检测之间的一致性
Appl Immunohistochem Mol Morphol. 2010 May;18(3):268-72. doi: 10.1097/PAI.0b013e3181cddde9.
7
Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.基于微阵列的乳腺癌雌激素受体、孕激素受体和 HER2 受体状态的测定。
Clin Cancer Res. 2009 Nov 15;15(22):7003-11. doi: 10.1158/1078-0432.CCR-09-0449. Epub 2009 Nov 3.
8
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.东部肿瘤协作组(ECOG)2197研究中的雌激素和孕激素受体状态:本地实验室与中心实验室免疫组织化学检测结果比较以及中心实验室定量逆转录聚合酶链反应检测结果比较
J Clin Oncol. 2008 May 20;26(15):2473-81. doi: 10.1200/JCO.2007.13.6424.
9
Current issues in ER and HER2 testing by IHC in breast cancer.乳腺癌免疫组化检测雌激素受体(ER)和人表皮生长因子受体2(HER2)的当前问题
Mod Pathol. 2008 May;21 Suppl 2:S8-S15. doi: 10.1038/modpathol.2008.34.
10
The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer.固定、处理及评估标准对乳腺癌激素受体免疫组化检测的影响
Breast Cancer. 2007;14(2):182-8. doi: 10.2325/jbcs.976.